Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals

“On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement,”

Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals

“Keith was integral to Syndax's transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success.”

Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals

“We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.”

Aaron A. Ondrey, Chief Financial Officer of Syndax Pharmaceuticals

“I am thrilled to join Syndax at such a pivotal moment in the Company's evolution,”

Aaron A. Ondrey, Chief Financial Officer of Syndax Pharmaceuticals

“Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company's leadership position and its strong financial foundation.”

Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals

“It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team,”

Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals

“I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future.”